Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Is Feasible After Solid Organ Transplantation: A Retrospective Analysis By The Early Complications Subcommittee Of The Complications and Quality Of Life Working Party, EBMT

Grzegorz W. Basak, MD, PhD, Wieslaw W. Jedrzejczak, MD, PhD, Helene Schoemans, MD, Per T. Ljungman, MD, PhD, Guido Kobbe, MD, Yves Beguin, MD, PhD, Peter Lang, MD, Karl-Walter Sykora, MD, Liane CJ te Boome, MD, Anja van Biezen, Steffie van der Werf, Mohamad Mohty, MD, PhD, Theo de Witte, MD, Judith Marsh, Peter Dreger, MD, Nicolaus Kroeger, MD, Rafael F. Duarte, MD, PhD, Tapani Ruutu, MD PhD

Blood (2013) 122 (21): 2110.

https://doi.org/10.1182/blood.V122.21.2110.2110

Published: 2013

Journal Articles

Risk Factors for Post-Transplant Lymphoproliferative Disorder in Solid Organ Transplant Recipients

Mark E Lustberg, MD, PhD, Ronald Pelletier, MD, Pierluigi Porcu, MD, Stanley Martin, MD, Robert A. Baiocchi, M.D., Ph.D.

Blood (2011) 118 (21): 4465.

https://doi.org/10.1182/blood.V118.21.4465.4465

Published: 2011

Journal Articles

Monoclonal Gammopathy of Undetermined Significance (MGUS) Does Not Affect Outcomes in Patients Undergoing Solid Transplants.

Victor H Jimenez-Zepeda, Raymond Heilman, MD, David Mulligan, MD, A. Keith Stewart, MD

Blood (2009) 114 (22): 2834.

https://doi.org/10.1182/blood.V114.22.2834.2834

Published: 2009

Journal Articles

Fixed-Dose Single Administration of Pegfilgrastim vs Daily Filgrastim in Patients with PTLD Undergoing a Sequential Therapy of Rituximab and CHOP Chemotherapy.

Ralf Trappe, MD, Papp-Vary Matthias, Stephan Oertel, MD, Riess Hanno, MD

Blood (2005) 106 (11): 4724.

https://doi.org/10.1182/blood.V106.11.4724.4724

Published: 2005

Journal Articles

Sequential Treatment with the Anti-CD 20 Antibody Rituximab and CHOP+GCSF Chemotherapy in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD): First Interim Analysis of a Multicenter Phase II Study.

Ralf Trappe, MD, Stephan Oertel, MD, Sylvain Choquet, MD, Vernoique LeBlond, MD, Matthias Papp-Vary, Hanno Riess, MD

Blood (2005) 106 (11): 932.

https://doi.org/10.1182/blood.V106.11.932.932

Published: 2005

Journal Articles

Acquired Pure Red Cell Aplasia Associated with Alemtuzumab, Mycophenolate, and Daclizumab Immunosuppression after Pancreas Transplant.

Milena Elimelakh, MD, Vanessa Dayton, MD, Katharine S. Park, MD, Rainer W. Gruessner, MD, Angelika C. Gruessner, PhD, David E. Sutherland, MD, Barbara Bland, MS, MLIS, RN, Robert B. Howe, MD, Jo-Anne van Burik, MD, Aneel A. Asraani, MD, Mark T. Reding, MD, Tim P. Singleton, MD, Nigel S. Key, MB, FRCP

Blood (2005) 106 (11): 1058.

https://doi.org/10.1182/blood.V106.11.1058.1058

Published: 2005

NARROW

Allogeneic Hematopoietic Stem Cell Transplantation Is Feasible After Solid Organ Transplantation: A Retrospective Analysis By The Early Complications Subcommittee Of The Complications and Quality Of Life Working Party, EBMT

Risk Factors for Post-Transplant Lymphoproliferative Disorder in Solid Organ Transplant Recipients

Monoclonal Gammopathy of Undetermined Significance (MGUS) Does Not Affect Outcomes in Patients Undergoing Solid Transplants.

Fixed-Dose Single Administration of Pegfilgrastim vs Daily Filgrastim in Patients with PTLD Undergoing a Sequential Therapy of Rituximab and CHOP Chemotherapy.

Sequential Treatment with the Anti-CD 20 Antibody Rituximab and CHOP+GCSF Chemotherapy in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD): First Interim Analysis of a Multicenter Phase II Study.

Acquired Pure Red Cell Aplasia Associated with Alemtuzumab, Mycophenolate, and Daclizumab Immunosuppression after Pancreas Transplant.

Email alerts

ASH Publications

American Society of Hematology

Allogeneic Hematopoietic Stem Cell Transplantation Is Feasible After Solid Organ Transplantation: A Retrospective Analysis By The Early Complications Subcommittee Of The Complications and Quality Of Life Working Party, EBMT

Risk Factors for Post-Transplant Lymphoproliferative Disorder in Solid Organ Transplant Recipients

Monoclonal Gammopathy of Undetermined Significance (MGUS) Does Not Affect Outcomes in Patients Undergoing Solid Transplants.

Fixed-Dose Single Administration of Pegfilgrastim vs Daily Filgrastim in Patients with PTLD Undergoing a Sequential Therapy of Rituximab and CHOP Chemotherapy.

Sequential Treatment with the Anti-CD 20 Antibody Rituximab and CHOP+GCSF Chemotherapy in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD): First Interim Analysis of a Multicenter Phase II Study.

Acquired Pure Red Cell Aplasia Associated with Alemtuzumab, Mycophenolate, and Daclizumab Immunosuppression after Pancreas Transplant.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only